Background. The prevalence of fluoroquinolone (FQ) resistance among Escherichia coli and Klebsiella pneumoniae has increased markedly in recent years. However, the impact of FQ resistance on mortality remains unknown.
The fluoroquinolone (FQ) class of antibiotics has been established as a vital component of the current antimicrobial arsenal [1] . The emergence of FQ resistance in Escherichia coli and Klebsiella pneumoniae is of great concern, because these pathogens account for 120% of all hospital-acquired infections [2, 3] . Recent reports have noted significant increases in the prevalence of FQ resistance among gram-negative bacilli during the past few years [4] [5] [6] . The emergence of FQ resistance among organisms also demonstrating resistance to multiple other antimicrobial agents (e.g., extended-spectrum blactamase [ESBL] resistance) is particularly concerning [7, 8] .
Few data exist regarding the impact of FQ resistance on clinical outcomes, particularly mortality. Studies focusing on the impact of other antimicrobial-resistant pathogens (e.g., methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, and ESBLproducing Enterobacteriaceae) have demonstrated outcomes that are significantly worse for patients infected with resistant pathogens, compared with patients infected with the pathogens' susceptible counterparts [9] [10] [11] . However, the association between resistance and outcome may also be confounded by other variables (e.g., underlying severity of illness) [12] . In addition, it has been suggested that acquisition of mutations conferring FQ resistance may be associated with decreased virulence [13, 14] . Thus, the potential impact of FQ resistance on mortality is unclear. We conducted a hospital-based retrospective cohort study involving a previously described study population [15] to specifically investigate the association between FQ resistance among and mortality due to infections with E. coli and K. pneumoniae.
SUBJECTS AND METHODS

Subjects.
The study was conducted at the following 2 University of Pennsylvania hospitals in Philadelphia: The Hospital of the University of Pennsylvania (HUP), an academic tertiary care medical center with 625 patient beds, and Presbyterian Medical Center (PMC), a 344-bed urban community hospital. The investigation was conducted over a 1.5-year period (1 January 1998 through 30 June 1999).
All clinical cultures demonstrating an E. coli and/or a K. pneumoniae isolate were identified through records of the clinical microbiology laboratory at HUP. This laboratory processes and cultures all specimens obtained at the participating hospitals. Identification and susceptibility testing of E. coli and K. pneumoniae isolates were performed by means of standard techniques, using a semiautomated system (MicroScan WalkAway System, NC16 panel; Dade Behring). Results were interpreted as described by the NCCLS [16] . Resistance to levofloxacin was used as a marker for resistance to FQs. An isolate was considered to be resistant if it demonstrated a levofloxacin MIC of у8 mg/mL. E. coli and K. pneumoniae isolates producing an ESBL were identified as described elsewhere [7] .
All patients with a FQ-resistant E. coli or K. pneumoniae isolate identified from the microbiology laboratory database were considered to be eligible for inclusion. All patients with a FQ-susceptible E. coli or K. pneumoniae isolate during the same period were also identified from this database. A number of patients equal to the total number of patients with FQresistant E. coli and K. pneumoniae isolates was randomly selected from the group of all patients with FQ-susceptible E. coli and K. pneumoniae isolates.
After the selection of eligible patients with FQ-resistant and FQ-susceptible isolates, medical records of these patients were reviewed to determine whether each patient met inclusion criteria. Of eligible subjects, only those whose isolates represented infection (as opposed to colonization), as defined by criteria of the Centers for Disease Control and Prevention [17] , were included. Furthermore, eligible subjects were included only if their isolates represented acquisition associated with health care. Infection was considered to be health care-acquired if у1 of the following was true: the infection occurred 148 h after hospital admission; the patient was admitted from another medical center or a long-term care facility, having spent 148 h in the other facility; and/or the patient had been hospitalized within the past 2 weeks.
Each patient was included in the study only once. If E. coli or K. pneumoniae was isolated on multiple occasions, only the first episode of infection was reviewed. For patients with an infection occurring during the first month of the study, the medical record was reviewed to ensure that another infection with the same organism did not occur in the preceding month. If such an infection had occurred in the preceding month, the patient was excluded.
Data collection. Data were ascertained through review of inpatient medical records. Data obtained included age, sex, race, location in the hospital at the time of infection, the number of hospital days before infection, the number of days in an intensive care unit (ICU) during the 30 days before infection, and the severity of illness at the time of infection (calculated according to the APACHE II classification system [18] ). The presence of an indwelling device (i.e., central venous catheter, urinary catheter, or mechanical ventilation) was also ascertained. Finally, the species of the infecting organism, the site of infection, the presence of bloodstream involvement, the presence of a coinfecting organism, and whether the infecting organism produced an ESBL were documented.
The presence of each of the following comorbid conditions was assessed at the time of infection: hepatic dysfunction, malignancy, diabetes mellitus, renal insufficiency, human immunodeficiency virus infection, neutropenia, corticosteroid use, previous transplantation, use of an immunosuppressive agent in the preceding 30 days, and surgical procedure or trauma in the preceding 30 days. Hepatic dysfunction was defined by у2 of the following conditions: a bilirubin concentration of 12.5 mg/dL, an aspartate aminotransferase or alanine aminotransferase level more than twice the upper limit of normal, and/or known liver disease. Neutropenia was classified as an absolute neutrophil count of !500 cells/mm 3 . Renal insufficiency was indicated by a creatinine concentration of 12.0 mg/dL. Corticosteroid use was defined as the receipt of prednisone at a dosage of у20 mg per day (or equivalent) for at least 2 weeks during the preceding 30 days.
The following features of the treatment for each infection were documented: the initial antimicrobial agent(s) chosen as empirical therapy in the first 48 h after the sample was obtained for culture; the final antibiotic(s) chosen on the basis of susceptibility test results, and the interval (in hours) between suspicion of infection (determined by the time at which the sample was obtained for culture) and initiation of adequate antimicrobial therapy (defined as an agent to which the infecting organism was susceptible).
Our primary outcome of interest was in-hospital mortality. Secondary analyses explored attributable mortality as an alternative outcome [11, [19] [20] [21] . In this definition, the possible outcomes were classified as follows: (1) "mortality directly attributable to infection," death during hospitalization in association with clinical evidence of active infection and a positive culture result; (2) "mortality indirectly attributable to infection," failure or further compromise of an organ system due to infection and death occurring during hospitalization as a result of organ failure; (3) "mortality unrelated to infection," death occurring during hospitalization after an episode of infection but due to causes independent of the infectious process; and (4) "survival," patient discharged alive from the hospital. The proportion of deaths directly and indirectly attributable to infection defined the "attributable mortality" [11, [19] [20] [21] .
Statistical methods. We first noted the number of patients with FQ-resistant infection and the number with FQ-susceptible infection. We then calculated mortality for the entire cohort, as well as for patients with FQ-resistant infection and for those with FQ-susceptible infection. We then characterized subjects in the cohort on the basis of baseline demographic characteristics (e.g., age and sex).
Bivariable analyses were conducted to determine the association between potential risk factors and mortality. Of primary interest was the association between FQ-resistant infection and mortality. Categorical variables were compared using Fisher's exact test. An OR and 95% CI were calculated to evaluate the strength of any association, as well as the precision of the estimate of the effect. ORs were calculated instead of relative risks to facilitate comparison of unadjusted and adjusted ORs in the multivariable analyses. Continuous variables were compared using the Wilcoxon rank-sum test [22] . Stratified analyses were then conducted to help identify where data were sparse and to elucidate where confounding and effect modification were likely to exist in multivariable analysis.
Adjusted ORs were calculated using multiple logistic regression analysis, with overall mortality as the dependent outcome [23] . The model for mortality began with inclusion of the primary risk factor of interest (i.e., FQ-resistant infection), which was based on our a priori hypothesis of an association between FQ-resistant infection and mortality. Other variables were considered for inclusion in a multivariable model if they were found to be associated with mortality on bivariable analysis ( ) or if they were involved in confounding on stratified P р .20 analysis [24] . These variables remained in the final multivariable model if their inclusion in the model resulted in a у15% change in the effect size of the primary association of interest (i.e., the association between FQ-resistant infection and mortality) [25] [26] [27] .
After performance of these primary analyses, we explored the hypothesis that one explanation for the association between FQ resistance and mortality is that infection with a FQ-resistant strain increases the likelihood that a patient will not receive an adequate empirical antimicrobial regimen. We first compared subjects who had FQ-resistant infection with subjects who had FQ-susceptible infection with regard to how quickly an adequate antimicrobial regimen was initiated. Inclusion of the variable for time to effective therapy in the final model was then explored to determine its impact on the primary association of interest (i.e., FQ-resistant infection and mortality). Because the hypothesis was that this variable was in the causal pathway between FQ-resistant infection and mortality, it was not retained in the final model.
For all calculations, a 2-tailed P value of !.05 was considered to be statistically significant. All statistical calculations were performed using standard programs in Stata, version 8.0 (Stata).
This study was reviewed and approved by the Committee on Studies Involving Human Beings of the University of Pennsylvania.
RESULTS
During the study period, 178 patients with FQ-resistant E. coli or K. pneumoniae isolates were identified from the database of the clinical microbiology laboratory. Of 3278 patients with FQsusceptible isolates, 178 were randomly selected to equal the number of subjects with FQ-resistant isolates. Of the 178 patients with FQ-resistant isolates, 42 were ineligible for the study because their isolates represented colonization and/or community acquisition; 96 of 178 patients with FQ-susceptible isolates were also ineligible for this reason. Of 136 eligible subjects with FQ-resistant, health care-acquired E. coli or K. pneumoniae infection, 123 (90%) had complete medical records available for review. Of 82 eligible subjects with FQ-susceptible, health care-acquired E. coli or K. pneumoniae infection, 70 (85%) had complete medical records available.
The median age for all 193 patients was 72 years (range, 22-100 years; 95% CI, 69-75 years). A total of 121 patients (62.7%) were female. Of 183 patients for whom race was noted, 67 (36.6%) were white, 109 (59.6%) were African American, 5 (2.7%) were Latino, and 2 (1.1%) were Asian. One hundred twenty-five patients (64.8%) were hospitalized at HUP, compared with 68 (35.2%) who were hospitalized at PMC. Of 193 patients, 149 (77.2%) had E. coli infection, whereas 44 (22.8%) had K. pneumoniae infection. The locations of infection were as follows: urinary tract, 131 patients (67.9%); bloodstream, 25 (13.0%); wound, 19 (9.8%); respiratory tract, 15 (7.8%); and central venous catheter, 2 (1.0%). One patient (0.5%) had an intra-abdominal infection.
Of 123 patients with FQ-resistant infection, 16 (13.0%) died, compared with 4 (5.7%) of 70 patients with FQ-susceptible infection (OR, 2.47; 95% CI, 0.75-10.53;
]. Variables P p .10 with a statistically significant association or a borderline, nonstatistically significant association with mortality are shown in table 1. Of note, ESBL production by the infecting organism (table 2) . Other variables included in P p .04 the final multivariable model are also shown in table 2. When these analyses were repeated using attributable mortality rather than crude in-hospital mortality as the outcome, the results were not substantively different.
Among the 193 patients, treatment with 213 antibiotics with activity against E. coli and K. pneumoniae was initiated as empirical therapy within 48 h after samples were obtained for culture (some subjects received 11 agent) (figure 1). The most commonly used empirical antibiotics were levofloxacin, aminoglycosides, and ampicillin-sulbactam. Of 41 empirical courses of aminoglycosides, 33 (80.5%) were used in combination with another agent possessing activity against E. coli and K. pneumoniae.
The precise timing of antimicrobial therapy initiated for the E. coli or K. pneumoniae infection was available for 98 subjects. The median interval between obtaining a sample for culture and initiating adequate antibiotic therapy (defined as at least 1 agent to which the infecting organism was susceptible) was 51 h (95% CI, 26-71 h) for patients with FQ-resistant infection, compared with 16 h (95% CI, 8-23 h) for patients with a FQ- susceptible infection ( , by the Wilcoxon rank-sum test). P ! .001 A significantly smaller proportion of patients with FQ-resistant infection received adequate antimicrobial therapy within both the 24-h and 48-h periods after samples were obtained for culture, compared with patients with FQ-susceptible infection (figure 2). Inclusion of the variable for time to effective therapy in the final model revealed that there was no longer a significant association between FQ-resistant infection and mortality (adjusted OR, 2.53; 95% CI, 0.50-12.7;
). P p .26
DISCUSSION
This study found that FQ resistance was significantly associated with mortality among hospitalized patients with E. coli and K. pneumoniae infections, even after controlling for other significant risk factors for mortality. Furthermore, patients with FQresistant infection were significantly less likely to have received empirical antimicrobial therapy with activity against the causative pathogen within the first 24 h and 48 h of infection than were patients with FQ-susceptible infection. This is the first study to our knowledge to find FQ resistance to be an independent risk factor for mortality. Recent small studies that have not found statistically significant differences in mortality rates in comparisons of patients infected with FQresistant E. coli or with FQ-susceptible E. coli were likely underpowered to demonstrate a clinically important difference [28, 29] . In addition, both previous studies focused only on specific patient populations (i.e., patients with cancer and/or cirrhosis) [28, 29] . Finally, previous studies failed to distinguish Figure 2 . Percentages of patients infected with fluoroquinolone (FQ)-resistant Escherichia coli or Klebsiella pneumoniae or with FQ-susceptible E. coli or K. pneumoniae who were receiving appropriate antibiotic therapy (defined as at least 1 agent to which the infecting organism was susceptible) р24 h and р48 h after samples were obtained for culture.
colonizing isolates from infecting isolates, despite the fact that isolates associated with colonization would presumably be much less likely to affect mortality [28] .
One possible explanation for the association between FQ resistance and mortality is that FQ-resistant E. coli and K. pneumoniae are more virulent than their FQ-susceptible counterparts. However, the few existing data suggest the oppositethat expression of virulence factors and causation of more-invasive clinical disease is more common among FQsusceptible isolates [13, 14, 30] .
Another possible explanation of the association between FQ resistance and mortality is that FQ resistance may result in a delay in the initiation of adequate antimicrobial therapy. In support of this contention, we noted that the time required to receive adequate antimicrobial therapy was significantly longer for patients with FQ-resistant infection. It is likely that this delay in therapy may have led to worse clinical outcomes in this group. Indeed, the delay in initiation of adequate antimicrobial therapy has been noted to be an important predictor of mortality in ICU patients with bacteremia and in patients with ventilator-associated pneumonia [31, 32] .
The clinical use of FQs is extremely widespread [33, 34] . Indeed, levofloxacin was the most commonly prescribed empirical antibiotic in this study, with 51 (26.4%) of patients in our cohort receiving this agent. Recognizing the likely continued emergence of FQ resistance, how might our results inform efforts to decrease the clinical impact of FQ resistance? If FQ resistance leads to increased mortality through delays in initiation of appropriate therapy, future efforts might focus on better identifying patients at high risk of harboring a FQ-resistant pathogen and prescribing alternative agent(s) as empirical therapy. Efforts to develop such a clinical prediction rule should initially focus on previously identified risk factors for FQ-resistant infection, such as recent FQ use, long-term care facility residence, and total prior antibiotic use [15, 35, 36] .
There were several potential limitations to our study. Although the possibility of selection bias may be of concern in a cohort study, all study subjects were identified through the same microbiology laboratory that processes all bacterial cultures for the participating institutions. Of patients with E. coli and K. pneumoniae isolates, all patients whose isolates were FQ resistant were eligible for inclusion, whereas a random sample of patients with FQ-susceptible isolates was selected as eligible unexposed subjects. After a subsequent review of medical records to determine whether predetermined eligibility criteria were met, a greater number of eligible unexposed patients than eligible exposed patients were excluded. This discrepancy is, however, unlikely to have introduced a differential bias, because, on the basis of information in the microbiology database, all eligible exposed patients and a random sample of all eligible unexposed subjects were selected. Thus, the potential of selection bias was likely small, apart from bias introduced because of lost charts, which did not differ substantially between the exposed and unexposed groups.
Although misclassification bias is likewise of concern, all study subjects were drawn from the same hospitalized patient population, and exposed and unexposed patients were identified solely on the basis of antimicrobial susceptibility data. Because these tests were conducted before the occurrence of the primary outcome of interest (i.e., mortality), there is unlikely to have been any differential misclassification bias. As in any observational study, the potential for unmeasured confounding must be recognized. However, we assessed all variables that were demonstrated or hypothesized to be associated with mortality in past studies of antimicrobial resistance. Finally, our study was conducted in a large tertiary care medical center and a smaller urban community hospital, and the results may not be generalizable to other institutions.
In conclusion, we found FQ resistance to be an independent risk factor for mortality among hospitalized patients with E. coli and K. pneumoniae infections. Furthermore, patients with FQ-resistant infections were significantly less likely to have received adequate antimicrobial therapy within the first 24 h and 48 h of infection. This work highlights the grave implications of the emergence of FQ resistance. As such, it underscores the urgency of efforts to more clearly elucidate the epidemiology of FQ resistance, to design effective interventions to limit further emergence of resistance to these agents.
